Targeted Protein Degradation in Inflammation and Cancer Therapy, Upcoming Webinar Hosted by Xtalks

Share Article

In this free webinar, the featured speakers will discuss PROTAC technology and challenges in the field as well as opportunities and strategies for developing PROTACs in cancer and inflammation. Attendees will learn about the available tools and assays for mechanistic profiling and DMPK optimization for oral bioavailability.

This webinar will focus on our efforts with PROTACs in the areas of inflammation and cancer.

Proteolysis targeting chimera or PROTAC is a novel drug discovery strategy that has brought a paradigm shift and significant opportunity to transform the way medicinal chemistry and drug discovery programs are currently planned and executed. With sub-stoichiometric catalytic mode of action, PROTACs reduce the need for target occupancy as necessitated with traditional small molecule inhibitors. PROTACs hold great promise to target highly mutable kinases and signalling proteins, which promote cancer and drug resistance (e.g., KRAS, BRAF and EGFR).

This webinar will focus on our efforts with PROTACs in the areas of inflammation and cancer. Specifically, we will discuss challenges and opportunities for developing PROTACs in the areas of autoimmune and inflammatory diseases driven by IL-1R/TLR1 signaling and inflammasome activation and in potentially undruggable epigenetic pathways that involve bromodomain proteins, histone acetyltransferases and deacetylases.

The webinar will also address some of the DMPK challenges in developing PROTACs and strategies and optimizations that might aid the development of orally bioavailable PROTAC candidates.

Join Amar Thyagarajan, Ph.D., Global Strategy Head and Head of North America BD (Biology Solutions), GVK Biosciences and Aragen Biosciences and Venkatesh Babu Jayaraman, Principal Scientific Manager, GVK Biosciences in a live webinar on Friday, October 30, 2020 at 11am EDT (3pm GMT/UK).

For more information or to register for this event, visit Targeted Protein Degradation in Inflammation and Cancer Therapy.


Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit
For information about hosting a webinar visit

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Sydney Perelmutter
+1 (416) 977-6555 x 352
Email >
Visit website